Edgewise Therapeutics (EWTX) Earnings Date, Estimates & Call Transcripts $27.35 -1.39 (-4.84%) (As of 12:27 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Edgewise Therapeutics Latest Earnings SummaryActual EPS (Nov. 7) -$0.36 Beat By $0.01 Consensus EPS (Nov. 7) -$0.37 Edgewise Therapeutics released Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.36, which beat the consensus estimate of -$0.37 by $0.01. With a trailing EPS of -$1.50, Edgewise Therapeutics' earnings are expected to decrease next year, from ($1.45) to ($1.79) per share. Get Edgewise Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edgewise Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataEWTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.EWTX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Edgewise Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.41-$0.30-$0.36Q2 20242-$0.43-$0.31-$0.37Q3 20242-$0.45-$0.35-$0.40Q4 20242-$0.44-$0.39-$0.42FY 20248-$1.73-$1.35-$1.54Q1 20251-$0.40-$0.40-$0.40Q2 20251-$0.49-$0.49-$0.49Q3 20251-$0.51-$0.51-$0.51Q4 20251-$0.53-$0.53-$0.53FY 20254($1.93)($1.93)($1.93) Edgewise Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/7/2024Q3 2024-$0.37-$0.36+$0.01-$0.36--8/8/2024--$0.36-$0.34+$0.02-$0.34--5/9/2024Q1 2024-$0.39-$0.33+$0.06-$0.33--2/22/2024Q4 2023-$0.44-$0.47 -$0.03-$0.47--11/9/2023Q3 2023-$0.40-$0.41 -$0.01-$0.41--8/10/2023Q2 2023-$0.41-$0.34+$0.07-$0.34-- Get the Latest News and Ratings for EWTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023-$0.37-$0.36+$0.01-$0.36--2/23/2023Q4 2022-$0.36-$0.31+$0.05-$0.31-- Edgewise Therapeutics Earnings - Frequently Asked Questions When did Edgewise Therapeutics announce their last quarterly earnings? Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earning data on Thursday, November 7, 2024. Learn more on EWTX's earnings history. Did Edgewise Therapeutics beat their earnings estimates last quarter? In the previous quarter, Edgewise Therapeutics (NASDAQ:EWTX) reported ($0.36) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.37) by $0.01. Learn more on analysts' earnings estimate vs. EWTX's actual earnings. How much profit does Edgewise Therapeutics generate each year? Edgewise Therapeutics (NASDAQ:EWTX) has a recorded net income of -$100.16 million. EWTX has generated -$1.50 earnings per share over the last four quarters. What is Edgewise Therapeutics's EPS forecast for next year? Edgewise Therapeutics's earnings are expected to decrease from ($1.45) per share to ($1.79) per share in the next year. More Earnings Resources from MarketBeat Related Companies Vaxcyte Earnings Results Qiagen Earnings Results Intra-Cellular Therapies Earnings Results Roivant Sciences Earnings Results Ascendis Pharma A/S Earnings Results Revolution Medicines Earnings Results Lantheus Earnings Results Legend Biotech Earnings Results Nuvalent Earnings Results Elanco Animal Health Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover This page (NASDAQ:EWTX) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredViral Trump video releasedPorter Stansberry’s latest video is going viral… In this bombshell exposé, famed economist Porter Stansberr...Porter & Company | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
